Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 5, 2016
Pharmacy Choice - News - Pharmaceutical Development - December 5, 2016

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/5/16 - 100 pharma cos join hands with CDSCO, PvPI to frame guidelines for good PvP practices [UMCI News]
Aimed at ushering in good pharmacovigilance practices in the country for drug safety, around 100 pharma companies have joined hands with Central Drugs Standard Control Organisation and Pharmaco-vigilance Programme of India to come up a set of exhaustive guidelines on par with the existing global guidelines. Pharmaco-vigilance programme of India had
12/5/16 - 15 Biggest Mid-Day Gainers For Monday
Biomerica, Inc. shares surged 27.7 percent to $2.68. Neuroderm Ltd shares jumped 26.7 percent to $19.70 as the company disclosed that it will replace two Phase 3 clinical trials with small pharmacokinetic trials following the FDA meeting on ND0612 regulatory development. Stone Energy Corporation gained 23.7 percent to $8.55. Stone Energy shares hav
12/5/16 - Ability to Delay Type 2 Diabetes Disease Progression by Preserving Beta Cell Mass Observed in New Imeglimin Data
POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes, today announced the presentation of preclinical data supporting Imeglimin s drug profile as a novel diabetes therapy. We are continuing to add further differentiating data to Imeglimin s exciting clinical results as we learn more
12/5/16 - Acceleron and Celgene Announce Preliminary Results from an Investigator Initiated Phase 2 Study of Sotatercept in Myelofibrosis at the 58th Annual Meeting of the American Society of Hematology
CAMBRIDGE, Mass.& SUMMIT, N.J. Acceleron Pharma Inc. and Celgene Corporation, today announced preliminary results from an ongoing investigator initiated Phase 2 study with investigational drug sotatercept in patients with myelofibrosis at the 58 th Annual Meeting of the American Society of Hematology in San Diego, California. Sotatercept is bei
12/5/16 - Acorda to Discontinue Development of Dalfampridine for Treatment of Post-Stroke Walking Difficulties
By a News Reporter-Staff News Editor at Clinical Trials Week Acorda Therapeutics, Inc. announced that the MILESTONE clinical study did not show sufficient efficacy to support further development of dalfampridine to improve post-stroke walking difficulties. I want to express our gratitude to the study participants, their care partners and clinicia
12/5/16 - Aegerion Pharmaceuticals, a Subsidiary ofNovelionTherapeutics, Enters into Agreement in Principle to Settle Class Action Shareholder Lawsuit
Novelion Therapeutics Inc., a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that on December 3, 2016, Aegerion Pharmaceuticals, an indirect, wholly-owned subsidiary of Novelion, entered into an agreement in principle to settle all claims in the class action shareho
12/5/16 - Alembic Pharma gets US FDA nod for anti-migraine drug [Cyprus Mail]
Alembic Pharmaceuticals has received approval from the US health regulator for Zolmitriptan orally disintegrating tablets, used for the treatment of migraine, in the American market. The company has received approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Zolmitriptan Orally Disintegrating Tablets, 2.5
12/5/16 - Alembic Pharmaceuticals gets USFDA approval for Zolmitriptan Orally Disintegrating Tablets [India Infoline News Service]
Alembic now has a total of 51 ANDA approvals from USFDA. Alembic Pharmaceuticals Limited announced that the company has received approval from the US Food& Drug Administration for its Abbreviated New Drug Application for Zolmitriptan Orally Disintegrating Tablets, 2.5 mg and 5 mg. Alembic Pharmaceuticals Ltd is currently trading at Rs 631.9, down b
12/5/16 - Alembic Pharmaceuticals Ltd drops 1.23% [India Infoline News Service]
Alembic Pharmaceuticals Limited announced that the company has received approval from the US Food& Drug Administration for its Abbreviated New Drug Application for Zolmitriptan Orally Disintegrating Tablets. Alembic Pharmaceuticals Ltd ended at Rs 624.45 down by Rs 7.80 or 1.23% from its previous closing of Rs 632.25 on the BSE. The scrip opened at
12/5/16 - ALNY In Motion, Shire Finds New Use For Old Drug, TFX Snaps Up VASC
SAINT HELIER- Alnylam Pharmaceuticals Inc., on Sunday, reported positive interim clinical results of its investigational RNAi therapeutic Fitusiran from an ongoing phase II open label extension study in patients with Hemophilia A or B without inhibitors. Acceleron Pharma Inc. and Celgene Corp., on Sunday, announced encouraging preliminary results f
12/5/16 - Alnylam Presents Updated Results from Phase 1/2 Study of ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today presented new results from Part C of its Phase 1/ 2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component 5 for the treatment of complement-mediated diseases, in a poster presentation at the 58th Annual...
12/5/16 - Alzheon to Present New Clinical Data and Analyses for ALZ-801, an Amyloid-Targeted Drug Candidate, and its Active Molecule Tramiprosate at the 9th...
Alzheon to Present New Clinical Data and Analyses for ALZ-801, an Amyloid-Targeted Drug Candidate, and its Active Molecule Tramiprosate at the 9th Clinical Trials on Alzheimer's Disease Congress. By a News Reporter-Staff News Editor at Clinical Trials Week Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicin
12/5/16 - Antibacterial Drug Resistance: Market Landscape, Challenges and Upcoming Opportunities, 2016-2026 - Research and Markets
Research and Markets has announced the addition of the "Antibacterial Drug Resistance: Market Landscape, Challenges and Upcoming Opportunities, 2016-2026" report to their offering. The "Antibacterial Drug Resistance: Market Landscape, Challenges and Upcoming Opportunities, 2016-2026" report provides an extensive study of the current landscape and t
12/5/16 - ARIAD Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients with CNS Metastases at the World Conference on Lung Cancer
~Investor and analyst call to be held on Wednesday, December 7 at 4:00 p.m. Central European Time. CAMBRIDGE, Mass.& VIENNA ARIAD Pharmaceuticals, Inc., a rare cancer-focused innovative biotechnology company, today announced clinical data on brigatinib, its investigational anaplastic lymphoma kinase inhibitor, from the ongoing Phase 1/ 2 and pi
12/5/16 - Astex Joins the Dementia Discovery Fund as a Strategic Investor
Release date- 26112016- Cambridge, UK- Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it has become a strategic investor in The Dementia Discovery Fund. Astex joins the DDF investor group whi
12/5/16 - Aurinia Highlights Renal Function Data from Global Phase IIb AURA Study of Voclosporin for Lupus Nephritis at American Society of Nephrology Kidney...
Aurinia Highlights Renal Function Data from Global Phase IIb AURA Study of Voclosporin for Lupus Nephritis at American Society of Nephrology Kidney Week 2016. By a News Reporter-Staff News Editor at Clinical Trials Week Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, announced...
12/5/16 - Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients
Release date- 02122016- Basel, Switzerland- Basilea Pharmaceutica Ltd. announced today the expansion of its ongoing oncology drug candidate BAL101553 clinical phase 1/ 2 a oral formulation study. Achim Kaufhold, Basilea's Chief Medical Officer, commented:' We are excited to explore BAL101553 in a separate glioblastoma study arm to our ongoing phase
12/5/16 - BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia at the 2016 American Society of Hematology Annual Meeting
BeiGene, Ltd. a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today presented updated clinical data from an ongoing Phase I study of BTK inhibitor BGB-3111 in patients with chronic lymphocytic leukemia and small lymphocytic leukemia at the 2016 American..
12/5/16 - Bellicum Pharmaceuticals Announces GoCAR-T and GoTCR Preclinical Presentations at the American Society of Hematology 2016 Annual Meeting
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the presentation of preclinical results on the Company s GoCAR-T and GoTCR technologies at the 58th American Society of Hematology Annual
12/5/16 - Bellicum Presents Clinical Results to Date of BPX-501 Pediatric Program and Provides Regulatory Update at Investor Event During ASH Annual Meeting
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, presented a review of results to date from its multicenter BP-004 clinical trial of BPX-501 in the pediatric setting, and provided an update on the regulato
12/5/16 - BerGenBio Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML at ASH 2016
Leading oncology biopharmaceutical company BerGenBio AS, today presented clinical and biological data from a Phase I trial of its potent, highly selective, first-in-class Axl inhibitor BGB324 in acute myeloid leukaemia in an oral session at the 58th ASH Annual Meeting& Exposition in San Diego. The company regards the results as an important indicat
12/5/16 - Bharat Book Bureau: Global Orphan Drug Clinical Pipeline Insight
As of 2016, almost 30 million people in the U.S. and 350 million people worldwide suffer from rare ailments known as "Orphan Diseases. As per the official definition, rare diseases are classified as those that affect fewer than 200,000 in the United States and less than 5 in 10,000 in the EU. Nevertheless, the Scenario has changed after the Orphan
12/5/16 - Biogen Inc. Renews License with Absorption Systems for Testing Platform
By a News Reporter-Staff News Editor at Clinical Trials Week- HYPERLINK " http://www.absorption.com/"\ nAbsorption Systems, a world leader in novel test systems for drug transporters, announces the renewal of a technology licensing deal with Biogen. Drug transporters such as P-gp have received increasing attention from drug regulatory bodies such
12/5/16 - BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase 2 a correlative data, as well as detailed mechanism-of-action data, for BL-8040, the Company's leading oncology platform at the ongoing 58th American Society of Hematology Annual.
12/5/16 - Biothera Pharmaceuticals and Merck Expand Research Collaboration to Include Phase 2 Clinical Trial in Head and Neck Cancer
Biothera Pharmaceuticals, Inc. today announced an expansion of its research collaboration with Merck to include a Phase 2 clinical study investigating Biothera s Imprime PGG in combination with KEYTRUDA , Merck s anti-PD-1 therapy, in second- and third-line patients with head and neck squamous cell cancer. A previously announced agreement b
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415